Product Information
AUSTEDO XR 30 MG TABLET is a brand product labeled by Teva Neuroscience, Inc., priced at $332.3400 per EA under NDC 68546047356. Its NADAC has been published 94 times since Dec 18, 2024.
FDA first approved this application on Feb 17, 2023.
Strength
30 mg/1
Manufacturer
Teva Neuroscience, Inc.NDC
68546047356
Classification
Brand
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DEUTETRABENAZINEApproval Type
New Drug (NDA)
FDA Application
NDA216354FDA Approved
2/17/2023
On Market Since
5/29/2024
Price Statistics
The NADAC for AUSTEDO XR 30 MG TABLET has been published 94 times since Dec 18, 2024, and over the history we have for it it has risen 7.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $332.3400 per EA |
|---|---|
| All-time high | $334.5410 (May 13, 2026) |
| All-time low | $308.2134 (Dec 18, 2024) |
| 52-week high | $334.5410 |
| 52-week low | $316.2449 |
| Median price | $317.2457 |
| Average price | $323.3538 |
| Largest weekly change | +5.5% (Jan 7, 2026) |
| Weeks tracked | 94 |
| Tracking since | Dec 18, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the deutetrabenazine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Neuroscience, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
deutetrabenazine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AUSTEDO XR 30 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for AUSTEDO XR 30 MG TABLET, manufactured by Teva Neuroscience, Inc., is $332.3400 per EA (NDC 68546047356), effective Sep 30, 2026.
How has the price of AUSTEDO XR 30 MG TABLET changed over time?
Over the history we have for it, the NADAC for AUSTEDO XR 30 MG TABLET has risen 7.8%. It has been tracked across 94 weekly CMS publications since Dec 18, 2024.
What are the highest and lowest recorded NADAC prices for AUSTEDO XR 30 MG TABLET?
Since Dec 18, 2024, the NADAC for AUSTEDO XR 30 MG TABLET has ranged from a low of $308.2134 (Dec 18, 2024) to a high of $334.5410 (May 13, 2026), with a median of $317.2457 per EA.
Are there cheaper alternatives to AUSTEDO XR 30 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of AUSTEDO XR 30 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures AUSTEDO XR 30 MG TABLET?
AUSTEDO XR 30 MG TABLET (NDC 68546047356) is labeled by Teva Neuroscience, Inc., and CMS classifies it as a brand product.